Brind.
  1. NanoViricides, Inc. is developing NV-387, a broad-spectrum antiviral drug that targets viral infections and reduces cancer resurgence via anti-inflammatory effects like IL-6.
  2. NanoViricides, Inc. is developing NV-387 for MPox treatment to address the continuing epidemic in Africa.

Border contact in Cabinda province is driving mpox risk in the Democratic Republic of the Congo.

1 report, 1 independent Updated Aug 5
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Border contact in Cabinda province is driving mpox risk in the Democratic Republic of the Congo.

Who's involved

What this event is mainly about
CabindaDemocratic Republic of the Congo

Keep exploring

Part of

NanoViricides, Inc. is developing NV-387 for MPox treatment to address the continuing epidemic in Africa. All 1 developments

Within NanoViricides, Inc. is developing NV-387, a broad-spectrum antiviral drug that targets viral infections and reduces cancer resurgence via anti-inflammatory effects like IL-6.

The entities involved

Coverage

Newest first; wire copies grouped